The sarcopenia treatment market is projected to grow significantly, reaching a value of US$ 5,264.76 million by 2030, up from US$ 3,397.62 million in 2022.

This report outlines the current trends in the market, as well as the factors that are both promoting and obstructing the growth of the sarcopenia treatment sector.

An increase in awareness regarding sarcopenia and its detrimental effects on health is creating substantial opportunities for progress in healthcare and geriatric care. Numerous advocacy groups and organizations are actively working to enhance public understanding of sarcopenia. These entities collaborate with healthcare professionals to inform the public about various aspects of the condition, including its pathogenicity, at-risk populations, preventive measures, and treatment options, while emphasizing the importance of early diagnosis and intervention. In 2023, the Office on Women's Health (OWH) of the US Department of Health and Human Services initiated the national campaign "Stronger than Sarcopenia" to elevate awareness of this condition among women. Research conducted by Health and Human Services indicates that over 45% of the elderly population in the United States is affected by sarcopenia, with millions of younger individuals potentially at risk of developing this condition in the future. As part of the "Stronger than Sarcopenia" initiative, women are encouraged to engage in discussions about sarcopenia with their healthcare providers, undergo screenings for the condition, and pursue necessary treatments if needed.

Sarcopenia has also been integrated into the educational programs of medical schools and training courses for healthcare professionals, including physicians, nurses, and physical therapists. For instance, the OWH has partnered with Medscape Education to develop continuing medical education (CME) credits aimed at enhancing healthcare professionals' ability to identify and manage sarcopenia in their patients. Additionally, mainstream media has broadened its coverage of sarcopenia, featuring articles, news reports, and documentaries that highlight the condition. A study published in February 2022 in PubMed noted that the US Department of Health and Human Services is among the leading funding bodies in the country, supporting 1,604 research projects focused on sarcopenia. Furthermore, July 4 has been designated as World Sarcopenia Day starting in 2022. Consequently, the increasing awareness surrounding sarcopenia is expected to foster new growth opportunities within the sarcopenia treatment market in the years ahead.

The sarcopenia treatment market is categorized by treatment type, which includes vitamin D and calcium supplements, protein supplements, vitamin B12 supplements, and other options. In 2022, the segment for vitamin D and calcium supplements dominated the market share. This segment is projected to experience the highest compound annual growth rate (CAGR) of 6.5% from 2022 to 2030. Vitamin D, being a fat-soluble vitamin, plays a vital role in maintaining calcium balance and supporting healthy bone metabolism. Research has shown that vitamin D supplementation can be an effective dietary approach to mitigate the risk of sarcopenia. Older adults with insufficient vitamin D levels are particularly vulnerable to sarcopenia, which is often linked to falls, hospitalizations, and other negative health outcomes.

Key primary and secondary sources utilized in the preparation of the report on the sarcopenia treatment market include the Public Health Agency of Canada, the US Department of Health and Human Services, and the National Institutes of Health (NIH).

In summary, the sarcopenia treatment market is on an upward trajectory, driven by increased awareness, educational initiatives, and a growing understanding of the condition's implications. The focus on effective treatments, particularly through supplementation, is expected to play a crucial role in addressing the challenges posed by sarcopenia, especially among the aging population.